Drug Drug Interactions (DDI)
How to Choose the Right Test Systems for Your DMPK Studies
Test systems for DMPK in vitro studies are part of the very foundation of our company. Our labs were borne of...
Transporters of Emerging Importance in Drug Development: Beyond the Guidance Documents
Dr. Ogilvie’s presentation discusses critical literature and case studies which have been published following the FDA’s 2017 guidance revision, and covered...
In Vitro Induction Studies: Elements of Design and Important Considerations in Data Analysis
Why do induction studies? Induction potential is an important piece of the drug-drug interaction (DDI) component of an IND submission. Simply put, we...
Minding Your Binding: Plasma Protein Binding Potential Study Now Available at Our US Labs
While liver and intestine are important in ADME, behavior in blood is also crucial. When an orally administered drug or...
Important Considerations for the Conduct of In Vitro Drug Transporter Assays
Not only can drug transporters affect the absorption and excretion of drugs, they can be involved in pharmacokinetic-based drug-drug interactions...
To GLP or not to GLP?
That is the question. . . Knowing the answer may save you time and money Good Laboratory Practices (GLP) are...
In Vitro DDI Regulatory Guidance Reference Poster
At the 2018 Marbach Castle Drug-Drug Interaction Workshop in Germany, Dr. Brian Ogilvie, Vice President of Scientific Consulting, presented a comparison...
Further Research on the Drug-Drug Interaction Between Gemfibrozil and Repaglinide Presented
The clinically-relevant drug-drug interaction (DDI) between the dyslipidemia drug gemfibrozil and the antidiabetic repaglinide is well-documented throughout the literature. In...
Considerations In Response to Drug-Drug Interaction Guidances
Check out the recent IQ consortium publication: Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidances from...
XenoTech Scientists Publish Paper, Present Research Evaluating Ketoconazole and its Alternative Clinical CYP3A4-5 Inhibitors as Inhibitors of Drug Transporters
XenoTech scientists published a paper in Drug Metabolism and Disposition evaluating Ketoconazole and its alternative clinical CYP3A4-5 inhibitors as inhibitors of drug...
Learn more
about XenoTech’s Drug Transport Services
